Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?

Revolution Medicines (RVMD) has surged 134% and now carries a $40 billion market cap after the FDA approved Rasonque, its pancreatic cancer treatment that beat chemotherapy in clinical trials.

The approval validates the trial result that set the stock's run in motion. Stanley Druckenmiller's Duquesne Family Office positioned ahead of it, boosting its stake by 26.5% in Q2. That timing matters: a prominent macro investor added into the catalyst rather than chasing it afterward.

The author, however, is not chasing here. The analyst recommends waiting for a $5 billion reduction in market cap before buying, which would put the entry near a $35 billion valuation. The stated reasoning is margin of safety in a volatile biotech sector. Interpretation: a 134% advance with the approval now delivered leaves less room for upside surprise, and the call frames the risk/reward as stretched at current levels rather than broken.

Warrants (RVMDW) trade alongside the common stock and would be expected to move with RVMD, though the article offers no pricing detail on them.